Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499150 | 0.82 | MAPT (0.38) | MAPTUTS2RAHCYMCHR1HTR2C | |
| SCHEMBL499213 | 0.82 | UTS2R (0.35) | MAPTUTS2RAHCYMCHR1HTR2C | |
| SCHEMBL498970 | 0.80 | UTS2R (0.34) | MAPTUTS2RAHCYKDM4EGAA | |
| SCHEMBL499535 | 0.80 | RIPK1 (0.38) | SLC6A4 | |
| SCHEMBL498979 | 0.78 | UTS2R (0.33) | MAPTUTS2RAHCYPDK2KDM4E | |
| SCHEMBL499588 | 0.78 | IDO1 (0.39) | MAPTUTS2RAHCYKDM4EALDH1A1 | |
| SCHEMBL31462773 | 0.77 | CCNE2 (0.35) | UTS2RMCHR1HTR2CSLC6A4PDK2 | |
| SCHEMBL499066 | 0.76 | MAPT (0.39) | MAPTUTS2RAHCYMCHR1HTR2C | |
| SCHEMBL4756782 | 0.74 | IDO1 (0.37) | MAPTAHCYKDM4EALDH1A1LMNA | |
| SCHEMBL31462720 | 0.74 | AHCY (0.37) | MAPTAHCYKDM4EGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | MAPT 935/4885UTS2R 520/4885AHCY 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.